Common Contracts
2 similar Exclusive License Agreement contracts by Galena Biopharma, Inc.
EX-10.65 13 d452403dex1065.htm EX-10.65 Execution Version [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of...Exclusive License Agreement • May 5th, 2020 • New York
This Amended and Restated Exclusive License Agreement (the “Agreement”) is effective as of the date of the last signature below (“Effective Date”), and is by and between MEMORIAL SLOAN KETTERING CANCER CENTER (hereinafter referred to as “MSK”), a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, and SELLAS LIFE SCIENCES GROUP LTD. (or its successor/assignee) an exempted limited company incorporated under the laws of Bermuda with offices at O’Hara House, 3 Bermudian Road, Hamilton HM 11, Bermuda, (“Licensee”). MSK and Licensee are sometimes referred to singly as “Party” and collectively as “Parties”.
AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT for MSK’s technology WT1 Peptide Vaccine TechnologyExclusive License Agreement • October 30th, 2017 • Galena Biopharma, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Exclusive License Agreement (the “Agreement”) is effective as of the date of the last signature below (“Effective Date”), and is by and between MEMORIAL SLOAN KETTERING CANCER CENTER (hereinafter referred to as “MSK”), a New York not-for-profit corporation with principal offices at 1275 York Avenue, New York, NY 10065, and SELLAS LIFE SCIENCES GROUP LTD. (or its successor/assignee) an exempted limited company incorporated under the laws of Bermuda with offices at O’Hara House, 3 Bermudian Road, Hamilton HM 11, Bermuda, (“Licensee”). MSK and Licensee are sometimes referred to singly as “Party” and collectively as “Parties”.
